협심증 치료제 시장 규모, 점유율, 성장 분석 : 약물 종류별, 종류별, 투여 경로별, 유통 경로별, 지역별 - 업계 예측(2026-2033년)

Global Angina Pectoris Drugs Market size was valued at USD 8.52 Billion in 2024 and is poised to grow from USD 8.99 Billion in 2025 to USD 13.85 Billion by 2033, growing at a CAGR of 5.52% during the forecast period (2026-2033).

The global angina pectoris drugs market is primarily fueled by an increasing and aging population alongside the rising incidence of ischemic heart disease, leading to heightened demand for both symptomatic and preventive treatments. The market encompasses various therapeutic options, including short- and long-acting nitrates, beta blockers, calcium channel blockers, as well as newer agents like ranolazine and ivabradine, all crucial for improving patient quality of life and reducing hospitalizations. Additionally, the rise of generics and expanded healthcare access in emerging markets drive volume growth and enable differentiation, as the loss of exclusivity of costly brand-name drugs results in reduced prices and broader prescribing opportunities. AI's integration into drug discovery enhances target identification, molecule design, and trial efficiency, focusing on novel mechanisms for better long-term symptom management.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Angina Pectoris Drugs market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Angina Pectoris Drugs Market Segments Analysis

Global angina pectoris drugs market is segmented by drug class, type, route, distribution and region. Based on drug class, the market is segmented into Nitrates, Beta-Blockers, Calcium Channel Blockers, Ranolazine (Ranexa) and Ivabradine. Based on type, the market is segmented into Stable Angina, Unstable Angina and Vasospastic (Variant) Angina. Based on route, the market is segmented into Oral, Sublingual, and Transdermal. Based on distribution, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Online. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Angina Pectoris Drugs Market

One of the key market drivers for the global angina pectoris drugs market is the increasing prevalence of cardiovascular diseases, which has led to a rising demand for effective treatment options. As lifestyle changes, such as poor diet, physical inactivity, and increased stress, contribute to heart-related conditions, more individuals are experiencing symptoms of angina pectoris. This growing patient population necessitates advancements in pharmacological therapies to manage pain and improve quality of life. Additionally, ongoing research and development efforts focused on innovative drug formulations and targeted therapies further accelerate market growth, as healthcare providers seek novel solutions to address this significant health concern.

Restraints in the Global Angina Pectoris Drugs Market

One key market restraint for the global angina pectoris drugs market is the increasing focus on non-pharmacological treatment options, such as lifestyle modifications and interventional procedures like angioplasty and stenting. As healthcare providers and patients become more aware of the benefits of adopting healthy habits, including diet, exercise, and stress management, reliance on medication may decline. This growing preference for alternative treatment methods can limit the demand for angina pectoris drugs, thereby impacting overall market growth. Furthermore, the high costs associated with ongoing medication therapies may also deter patients from adhering to prescribed treatments.

Market Trends of the Global Angina Pectoris Drugs Market

The Global Angina Pectoris Drugs market is witnessing a significant shift towards personalized therapeutics, fundamentally transforming how angina is managed. This trend is driven by advancements in biomarker-driven stratification and pharmacogenomic insights, enabling clinicians to devise treatment plans tailored to individual patient profiles and comorbidities, thus enhancing prediction of therapeutic responses and minimizing trial-and-error approaches. Collaborative efforts among diagnostics companies, technology firms, and pharmaceutical developers are accelerating the availability of companion diagnostics and targeted formulations. As payers and healthcare providers increasingly favor precision medicine for better patient outcomes, investment in niche therapies and streamlined clinical decision support mechanisms is on the rise, fostering individualized prescribing pathways across various healthcare settings.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global Angina Pectoris Drugs Market Size by Drug Class & CAGR (2026-2033)

• Market Overview
• Nitrates
• Beta-Blockers
• Calcium Channel Blockers
• Ranolazine (Ranexa)
• Ivabradine

Global Angina Pectoris Drugs Market Size by Type & CAGR (2026-2033)

• Market Overview
• Stable Angina
• Unstable Angina
• Vasospastic (Variant) Angina

Global Angina Pectoris Drugs Market Size by Route & CAGR (2026-2033)

• Market Overview
• Oral
• Sublingual
• Transdermal

Global Angina Pectoris Drugs Market Size by Distribution & CAGR (2026-2033)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Online

Global Angina Pectoris Drugs Market Size & CAGR (2026-2033)

• North America (Drug Class, Type, Route, Distribution)
  • US
  • Canada
• Europe (Drug Class, Type, Route, Distribution)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Drug Class, Type, Route, Distribution)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Drug Class, Type, Route, Distribution)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Drug Class, Type, Route, Distribution)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Pfizer Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gilead Sciences (Ranexa)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Servier Laboratories (Ivabradine)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi SA
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mylan (Viatris)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Watson Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Forest Laboratories (Allergan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Actavis (Allergan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Noven Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Par Pharmaceutical
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lannett Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hi-Tech Pharmacal
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cadila Healthcare
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Intas Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations